Worthing-based pharmaceutical company Allergy Therapeutics has recently announced that it is to raise £10.6m, as the company enters what the company’s chief executive describes as a “transformational” period of growth.

The specialist vaccines company, whose headquarters are in Dominion Way, aim to use the funds to expand a clinical grass trial (to cure grass pollen-induced allergies), part-fund a new trial and continue to develop its varied product channels.

“Allergy Therapeutics is now well positioned for a transformational period of growth both with our marketed products and our R&D pipeline,” says Chief Executive Manuel Llobet.

“With this successful placing and subscription, we will expand our planned Phase III PQ Grass trial, scheduled to start in H2 2019, including a project to analyse pollen trends in the US to maximise the exposure of patients to grass pollen.

“We will also support the Acarovac Phase II trial and, looking further out, further progress our diversified pipeline of patient friendly, convenient to use products including Polyvac Peanut.”